{"id":32320,"date":"2018-01-01T11:03:44","date_gmt":"2018-01-01T16:03:44","guid":{"rendered":"https:\/\/sciencebusiness.technewslit.com\/?p=32320"},"modified":"2018-01-01T11:07:53","modified_gmt":"2018-01-01T16:07:53","slug":"happy-2018-here-are-our-most-read-articles-in-2017","status":"publish","type":"post","link":"https:\/\/technewslit.com\/sciencebusiness\/?p=32320","title":{"rendered":"Happy 2018 — Here Are Our Most Read Articles in 2017"},"content":{"rendered":"
\"Piglets\"<\/a>
(Andrew Martin, Pixabay)<\/figcaption><\/figure>\n

1 January 2018. Happy new year to our visitors. We want to thank the nearly 20,000 individuals who read Science & Enterprise since we started tracking the numbers through Google Analytics in April. Here are the most visited of our 539 posts in 2017, excluding the nearly 5,000 people who looked at the site’s home page. We look forward to continue reporting on more exciting stories about science for business people and enterprise for scientists in the year ahead.<\/p>\n

FDA, Emulate to Test Organs-on-Chips for Drug Toxins<\/a>
\n11 April 2017. A joint venture between Food and Drug Administration and a developer of chip devices simulating human organs, is evaluating the chips as a way to test new drugs for toxic effects. FDA and\u00a0Emulate Inc.\u00a0in Boston, Massachusetts, a spin-off enterprise from the Wyss Institute for Biologically Inspired Engineering at Harvard University, will assess the ability of organs-on-chips to fulfill regulatory needs for testing drugs, as well as food, dietary supplements, and cosmetics.<\/p>\n

Viruses Removed from Pig Organs for Human Transplants<\/a>
\n10 August 2017. Researchers in the U.S., Denmark, and China devised a process with genome editing to remove viruses that prevent organs from pigs from being used for human transplants. The process is described by a team from the start-up company\u00a0eGenesis Inc.\u00a0in Cambridge, Massachusetts, with colleagues from Harvard University,\u00a0Aarhus University in Denmark, and several institutions in China, in today\u2019s issue of the journal\u00a0Science\u00a0(paid subscription required).<\/p>\n

Students Win Prize, Start Company for Alzheimer\u2019s Detection<\/a>
\n29 August 2017. A team of undergraduate students won first prize in a National Institutes of Health biomedical engineering contest for a headset device to diagnose early-stage Alzheimer\u2019s disease. The engineering students at\u00a0University of Maryland\u00a0in College Park, who received\u00a0notice of the award\u00a0on Friday, are also starting a company to take their invention to market.<\/p>\n

Patent Awarded for Live Bacterial Acne Treatment<\/a>
\n20 September 2017. A company developing treatments for disease by restoring the natural balance of bacteria on the skin received a patent for its acne therapy using spray-on live bacteria. The U.S. Patent and Trademark Office awarded patent number\u00a09,738,870\u00a0on 22 August to\u00a0AOBiome LLC\u00a0in Cambridge, Massachusetts. The three inventors on the patent include the two company\u00a0founders, David Whitlock and Spiros Jamas, and chief medical officer Larry Weiss.<\/p>\n

Nerve Stimulation Approved for Children\u2019s Epilepsy<\/a>
\n30 June 2017. The U.S. Food and Drug Administration approved use of vagus nerve stimulation to treat epilepsy in children who do not respond to drug therapy as young as 4 years old. The company\u00a0LivaNova PLC\u00a0in London, U.K. that makes the VNS Therapy system says FDA previously set the minimum age for its vagus nerve treatments for epilepsy at 12 years.<\/p>\n

Patent Set for Peptide Nerve Damage Treatments<\/a>
\n14 August 2017. The European Patent Office announced its intent to award a patent on treatments for nerve cell damage based on the peptide thymosin beta 4. The patent will be awarded to\u00a0Michael Chopp, a neuroscience researcher at Henry Ford Health System in Detroit, which licensed his discoveries to the company\u00a0RegeneRx Biopharmaceuticals Inc.\u00a0in Rockville, Maryland.<\/p>\n

*\u00a0\u00a0\u00a0\u00a0 *\u00a0\u00a0\u00a0\u00a0 *<\/p>\n","protected":false},"excerpt":{"rendered":"

Here are the most visited of our 539 individual posts, excluding the nearly 5,000 people who looked at the site’s home page.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[63],"tags":[],"class_list":["post-32320","post","type-post","status-publish","format-standard","hentry","category-administrative"],"_links":{"self":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/32320","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=32320"}],"version-history":[{"count":3,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/32320\/revisions"}],"predecessor-version":[{"id":32323,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/32320\/revisions\/32323"}],"wp:attachment":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=32320"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=32320"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=32320"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}